Ctt Pharmaceutical Holdings annual cash and equivalents
2009
2010
2011
2012
2013
2014
2024
2025
Ctt Pharmaceutical Holdings Cash & Equivalents Growth & History (CTTH)
Ctt Pharmaceutical Holdings's cash and equivalents was $15,359 for fiscal 2025.
View full Ctt Pharmaceutical Holdings company overviewCtt Pharmaceutical Holdings annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15,359 | $15,245 | +13372.81% |
| 2024 | 2024-12-31 | $114 | — | — |
| 2014 | 2014-12-31 | $81,179 | $81,179 | — |
| 2013 | 2013-12-31 | $0 | −$12,091 | — |
| 2012 | 2012-12-31 | $12,091 | −$557,287 | −97.88% |
| 2011 | 2011-12-31 | $569,378 | $523,187 | +1132.66% |
| 2010 | 2010-12-31 | $46,191 | −$224,977 | −82.97% |
| 2009 | 2009-12-31 | $271,168 | — | — |
Ctt Pharmaceutical Holdings quarterly cash and equivalents
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $31 | −$32,408 | −99.90% |
| Q1 2026 | 2026-03-31 | $7,089 | — | — |
| Q4 2025 | 2025-12-31 | $15,359 | $15,245 | +13372.81% |
| Q3 2025 | 2025-09-30 | $30,544 | — | — |
| Q2 2025 | 2025-06-30 | $32,439 | — | — |
| Q4 2024 | 2024-12-31 | $114 | — | — |
| Q3 2015 | 2015-09-30 | $32,121 | −$93,197 | −74.37% |
| Q2 2015 | 2015-06-30 | $46,073 | $42,404 | +1155.74% |
| Q1 2015 | 2015-03-31 | $73,447 | $68,902 | +1516.00% |
| Q4 2014 | 2014-12-31 | $81,179 | $81,179 | — |
| Q3 2014 | 2014-09-30 | $125,318 | $125,318 | — |
| Q2 2014 | 2014-06-30 | $3,669 | −$4,247 | −53.65% |
| Q1 2014 | 2014-03-31 | $4,545 | −$14,455 | −76.08% |
| Q4 2013 | 2013-12-31 | $0 | −$12,091 | — |
| Q3 2013 | 2013-09-30 | $0 | −$35,743 | — |
| Q2 2013 | 2013-06-30 | $7,916 | −$134,640 | −94.45% |
| Q1 2013 | 2013-03-31 | $19,000 | −$162,932 | −89.56% |
| Q4 2012 | 2012-12-31 | $12,091 | −$557,287 | −97.88% |
| Q3 2012 | 2012-09-30 | $35,743 | −$665,874 | −94.91% |
| Q2 2012 | 2012-06-30 | $142,556 | −$719,791 | −83.47% |
| Q1 2012 | 2012-03-31 | $181,932 | — | — |
| Q4 2011 | 2011-12-31 | $569,378 | $569,378 | — |
| Q3 2011 | 2011-09-30 | $701,617 | — | — |
| Q2 2011 | 2011-06-30 | $862,347 | — | — |
| Q4 2010 | 2010-12-31 | $0 | — | — |
Ctt Pharmaceutical Holdings cash and equivalents trends
Between the periods ended 2009-12-31 and 2025-12-31, Ctt Pharmaceutical Holdings's cash and equivalents decreased from $271,168 to $15,359, a change of −$255,809. The latest reported quarter, Q2 2026, shows $31.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ctt Pharmaceutical Holdings source filings ↗